Open Access
Nucleotide Polymerase Inhibitor So fos bu vir plus Ribavirin for Hepatitis C
E.J. Gane,Catherine A.M. Stedman,Robert H. Hyland,Xiao Ding,Evguenia S. Svarovskaia,William T. Symonds,R. Hindes,M.M. Berrey +7 more
TLDR
Sofosbuvir plus ribavirin for 12 weeks may be effective in previously untreated patients with HCV genotype 1, 2, or 3 infection, and the rate of sustained virologic response 24 weeks after therapy is reported.Abstract:
BACKGROUND The standard treatment for hepatitis C virus (HCV) infection is interferon, which is administered subcutaneously and can have troublesome side effects. We evaluated so fos bu vir, an oral nucleotide inhibitor of HCV polymerase, in interferon-sparing and interferon-free regimens for the treatment of HCV infection. METHODSread more
Citations
More filters
Journal ArticleDOI
EASL Recommendations on Treatment of Hepatitis C
Jean-Michel Pawlotsky,Alessio Aghemo,Geoffrey Dusheiko,Xavier Forns,Massimo Puoti,Christophe Sarrazin +5 more
TL;DR: The optimal management of patients with acute and chronic HCV infections in 2018 and onwards is described, as well as developments in diagnostic procedures and improvements in therapy and prevention.
Journal ArticleDOI
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz,Alessandra Mangia,David L. Wyles,Maribel Rodriguez-Torres,Tarek Hassanein,Stuart C. Gordon,Michael Schultz,M. Davis,Zeid Kayali,K. Rajender Reddy,Ira M. Jacobson,Kris V. Kowdley,L. Nyberg,G. Mani Subramanian,Robert H. Hyland,Sarah Arterburn,Deyuan Jiang,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Aasim Sheikh,Zobair M. Younossi,Edward Gane +23 more
TL;DR: In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks.
Journal ArticleDOI
Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
Yan Gao,Yan Gao,Liming Yan,Yucen Huang,Fengjiang Liu,Yao Zhao,Lin Cao,Tao Wang,Qianqian Sun,Zhenhua Ming,Lianqi Zhang,Ji Ge,Litao Zheng,Ying Zhang,Haofeng Wang,Haofeng Wang,Yan Zhu,Chen Zhu,Tianyu Hu,Tian Hua,Bing Zhang,Xiuna Yang,Jun Li,Haitao Yang,Zhi-Jie Liu,Wenqing Xu,Luke W. Guddat,Quan Wang,Zhiyong Lou,Zihe Rao +29 more
TL;DR: The structure of the COVID-19 virus polymerase essential for viral replication provides a basis for the design of new antiviral drugs that target viral RdRp, also named nsp12, and it appears to be a primary target for the antiviral drug remdesivir.
Journal ArticleDOI
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
Mark S. Sulkowski,David F. Gardiner,Maribel Rodriguez-Torres,K. Rajender Reddy,Tarek Hassanein,Ira M. Jacobson,Eric Lawitz,Anna S. Lok,Federico Hinestrosa,Paul J. Thuluvath,Howard J. Schwartz,David R. Nelson,Gregory T. Everson,Timothy Eley,Megan Wind-Rotolo,Shu-Pang Huang,Min Gao,Dennis Hernandez,Fiona McPhee,Diane Sherman,R. Hindes,William T. Symonds,Claudio Pasquinelli,Dennis M. Grasela +23 more
TL;DR: Once-daily oral daclatasvir plus sofosbuvir was associated with high rates of sustained virologic response among patients infected with HCV genotype 1, 2, or 3, including patients with no response to prior therapy with telaprevir or boceprevir.
Journal ArticleDOI
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
Ira M. Jacobson,Stuart C. Gordon,Kris V. Kowdley,Eric M. Yoshida,Maribel Rodriguez-Torres,Mark S. Sulkowski,Mitchell L. Shiffman,Eric Lawitz,Gregory T. Everson,Michael J. Bennett,Eugene R. Schiff,M. Tarek Al-Assi,G. Mani Subramanian,Di An,Ming Lin,John McNally,Diana M. Brainard,William T. Symonds,John G. McHutchison,Keyur Patel,Jordan J. Feld,Stephen Pianko,David R. Nelson +22 more
TL;DR: In patients with HCV genotype 2 or 3 infection for whom treatment with peginterferon and ribavirin was not an option, 12 or 16 weeks of treatment with sofosbuvir and ribvirin was effective.
References
More filters
Journal ArticleDOI
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders†‡§
Kazuaki Chayama,Shoichi Takahashi,Joji Toyota,Yoshiyasu Karino,Kenji Ikeda,Hiroki Ishikawa,Hideaki Watanabe,Fiona McPhee,Eric Hughes,Hiromitsu Kumada +9 more
TL;DR: Dual therapy with daclatasvir and asunaprevir, without Peg‐IFN and RBV, can achieve high SVR rates in difficult‐to‐treat patients with HCV genotype 1b infection and previous null response to Peg‐ifN andRBV.
Journal ArticleDOI
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward Gane,Stuart K. Roberts,Catherine A.M. Stedman,Peter W Angus,Brett Ritchie,Rob Elston,David Ipe,Peter N. Morcos,Linda Baher,Isabel Najera,Tom Chu,Uri Lopatin,M.M. Berrey,William Bradford,Mark Laughlin,Nancy S. Shulman,Patrick F. Smith +16 more
TL;DR: The combination of RG7128 and danoprevir was well tolerated with no treatment-related serious or severe adverse events, no grade 3 or 4 changes in laboratory parameters, and no safety-related treatment discontinuations.
Journal ArticleDOI
Surprisingly small effect of antiviral treatment in patients with hepatitis C.
Yngve Falck-Ytter,Hemangi Kale,Kevin D. Mullen,Steedman A. Sarbah,Lucian Sorescu,Arthur J. McCullough +5 more
TL;DR: The overall antiviral treatment rate and the reasons for nontreatment in a general population of HCV-infected patients in a metropolitan liver clinic are investigated.
Journal ArticleDOI
The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
Matthew F. McCown,Sonal Rajyaguru,Sophie Le Pogam,Samir Ali,Wen-Rong Jiang,Hyunsoon Kang,Julian Symons,Nick Cammack,Isabel Najera +8 more
TL;DR: Results indicate that the HCV replicon presents a higher barrier to the selection of resistance to nucleoside inhibitors than to nonnucleoside or protease inhibitors, which could have a clear clinical benefit through the delay of resistance emergence.
Journal ArticleDOI
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
TL;DR: By the introduction of direct antiviral drugs, hepatitis C therapy now is entering a new era in which the development of resistance may become the most important parameter for treatment success or failure.